During the SARS-Cov-2 pandemic, it is essential to identify the risk
factors that can cause a higher probability of infection and, therefore,
worsen the patient's health. In fact, the known risk factors include
already existing diseases and associated pharmacological treatments. A
patient with multiple sclerosis takes immunomodulatory drugs and
certainly has a high risk. Evidence and literature have shown that
SARS-Cov-2 infection causes severe lung damage due to a poorly
functioning immune system and overexpression of cytokines. Therefore the
management of multiple sclerosis treatments in immunomodulating therapy
must be carefully monitored. This article on the one hand analyzes and
recalls the safety profile of all drugs for multiple sclerosis, on the
other the recommendations adopted by different countries are
highlighted, trying to understand if the suspension of MS treatment must
actually materialize in order not to incur lethal covid pneumonia.